## **Tocilizumab (Actemra)**

Provider Order Form rev. 01/02/2024

Provider Name (print)

Patient Name: Patient Address: Patient Email: Aldregies:   NKD Weelst (Ebs/kg): Height (in/cm): Sex:   M /   F Date of Last Infusion: Next Due Date: Preferred Location:  DIAGNOSIS (Please provide ICD-10 code in space provided) Rheumatoid Arthritis: Cytokine Release Syndrome: Giant Cell Arteritis: Systemic Sclerosis Interstitial lung disease: Other:  THERAPY ADMINISTRATION  Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins  DOSING (Choose one)   RA/CRS: 4mg/kg x (	PATIENT INFORMATION	Referral Status	: □ New R	eferral 🗆 Updated	d Order        Order Renewal	
Allergies:   NKDA Weight (ibs/kg):   Height (in/cm):   Sex:   M /   F   Date of Last Infusion:   Next Due Date:   Preferred Location:    DIAGNOSIS (Please provide ICD-10 code in space provided) Rheumatoid Arthritis:   Cytokine Release Syndrome:   Giant Cell Arteritis:   Systemic Sclerosis Interstitial lung disease:   Other:    THERAPY ADMINISTRATION   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Close one!   LABORATORY ORDERS   Close (Widlift, AST, ALT at Week 4, then every 3 months   Lipid Panel at Week 4, then every 6 months   DOSING (Choose one)   PRE-MEDICATION ORDERS   Close (Widlift, AST, ALT at Week 4, then every 3 months   Lipid Panel at Week 4, then every 6 months   DOSING (Choose one)   PRE-MEDICATION ORDERS   Close (Widlift, AST, ALT at Week 4, then every 3 months   Lipid Panel at Week 4, then every 6 months   DOSING (Choose one)   PRE-MEDICATION ORDERS   PRE-MEDICATION ORDERS   Close (Widlift, AST, ALT at Week 4, then every 3 months   Lipid Panel at Week 4, then every 3 months   Lipid Panel at Week 4, then every 3 months   Lipid Panel at Week 4, then every 3 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 9 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then every 6 months   Lipid Panel at Week 4, then	Patient Name:		·			
Sex:   M     F   Date of Last Infusion:   Next Due Date:   Preferred Location:	Patient Address:	Patient Email:				
Sex:   M /   F   Date of Last Infusion:   Next Due Date:   Preferred Location:	Allergies:	-	□ NKDA	Weight (lbs/kg):	Height (in/cm):	
DIAGNOSIS (Please provide ICD-10 code in space provided)   Rheumatoid Arthritis:		Next Due Dat				
Rheumatoid Arthritis: Cytokine Release Syndrome: Giant Cell Arteritis:  Systemic Sclerosis Interstitial lung disease:  Other:  THERAPY ADMINISTRATION  Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins  DOSING (Choose one)  RA/CRS: 4mg/kg x (			<u></u>		<u></u>	
Systemic Sclerosis Interstitial lung disease:    Other:					<u>.</u>	
## LABORATORY ORDERS    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins    Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins   Actemptical (Actemra) in 100ml of 0.9% NS over 60mins   Actemptical (Actemra) in 100ml of 0.9% NS over 60mins   Actemptical (Actemra) in 100ml of 0.9% NS over 60mins   Actemptical (Actemra) in 100ml of 0.9% NS over 60mins   Actemptical (Actemptical (Actemptic	•	·		Giant Cell Artei	ritis:	
☑ Administer tocilizumab (Actemra) in 100ml of 0.9% NS over 60mins       ☑ CBC w/diff, AST, ALT at Week 4, then every 6 months         ØDOSING (Choose one)       ☐ CBC w/diff, AST, ALT at Week 4, then every 6 months         ☐ RA/CRS: 4mg/kg x (	Systemic Sclerosis Interstitial lung disease:	Ot	her:			
Preferred Contact Name:  Ordering Provider:  Referring Practice Name:  Provider NPI:  Referring Practice Name:  Provider NPI:  Referring Practice Address:  City:  State:  Zip Code:  REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval).  Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes the processing and insurance approval).	□ Administer tocilizumab (Actemra) in 100ml of 60mins      □ Choose one)      □ RA/CRS: 4mg/kg x ( kg) =	mg mg mg ) m	☑ CBC w/diff ☑ Lipid Pane  PRE-MEDI ☐ Tylenol ☐ ☐ Loratadine ☐ Pepcid 20i ☐ Benadryl [☐ Solumedro ☐ Other: ☐ NURSING ☑ Hold infus	f, AST, ALT at Week 4, el at Week 4, then ever the at least to 100,000 m or ALT no greater the and record weight at eursing care per Nursin vity Reaction Manage	ery 6 months  O  PO / IVP g IVP  er for: ness or active infection. procedures or recent live cigue, anorexia, dark urine, changes. n, ANC at least 1000 mm³ at least 2000mm³ nm³ an 1.5 times normal level each appointment ng Procedure, including	
Preferred Contact Name:  Ordering Provider:  Referring Practice Name:  Provider NPI:  Referring Practice Name:  Provider NPI:  Referring Practice Address:  City:  State:  Zip Code:  REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval).  Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes the processing and insurance approval).	DROVIDED INFORMATION					
Ordering Provider:  Referring Practice Name: Practice Address: Practice Address: City: State: Zip Code:  REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval). Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes			Preferred Contact Fmail:			
Referring Practice Name: Practice Address: City: State: Zip Code:  REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval). Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes the contraction of the contraction o						
Practice Address: City: State: Zip Code:  REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval, Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes the control of th		Ph				
REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval, Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN includes the contract of the co						
Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN inclu	DECLIDED DOCUMENTATION CHECKLY			uirad far praessins	•	
treatment failures or contraindications, biologic agents, steroids, and disease modifying agents  Required Labs: Negative Hepatitis B, Negative TB within 12 months, Rheumatoid factor, CRP, ESR, ANC, ALT, AST, Platelets	<b>Required Documentation:</b> Patient demos, copy treatment failures or contraindications, biologi	y of front and back of p c agents, steroids, and	orimary and s disease mod	secondary insurance difying agents	, 2 most recent OVN including	

Date

**Provider Signature**